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ABSTRACT 
 
We investigated the effect of 2-methyl-arachidonyl-2￿-fluoro-ethylamide (Met-F-AEA), a stable 
analog of the endocannabinoid anandamide, on a rat thyroid epithelial cell line (FRTL-5) 
transformed by the K-ras oncogene, and on epithelial tumors derived from these cells. Met-F-
AEA effect in vivo was evaluated in a nude mouse xenograft model, where K-ras-transformed 
(KiMol) cells were implanted subcutaneously. Met-F-AEA (0.5 mg/kg/dose) induced a drastic 
reduction in tumor volume. This effect was inhibited by the CB1 receptor antagonist SR141716A 
(0.7 mg/kg/dose) and was accompanied by a strong reduction of K-ras activity. Accordingly, 
KiMol cells and tumors express CB1 receptors. Met-F-AEA inhibited (IC50  ∼5  µM) the 
proliferation in vitro and the transition to the S phase of KiMol cells and it reduced K-ras 
activity; these effects were antagonized by SR141716A. Met-F-AEA cytostatic action was 
significantly smaller in nontransformed FRTL-5 cells than in KiMol cells. Met-F-AEA treatment 
exerted opposite effects on the expression of CB1 receptors in KiMol and FRTL-5 cells, with a 
strong up-regulation in the former case and a suppression in nontransformed cells. The data 
suggest that: 1) Met-F-AEA inhibits ras oncogene-dependent tumor growth in vivo through CB1 
cannabinoid receptors; and 2) responsiveness of FRTL-5 cells to endocannabinoids depends on 
whether or not they are transformed by K-ras. 
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as proteins (H-Ras, N-Ras, K-Ras4A, and K-Ras4B) are generally considered key 
molecular targets in the signal transduction pathways leading to cell proliferation, 
differentiation, or death. Ras functions as a molecular switch that cycles between an 
inactive guanosine 5￿-diphosphate (GDP)-bound form and an active guanosine 5￿-triphosphate 
(GTP)-bound state (1). The involvement of ras in uncontrolled growth is witnessed by the 
observation of increased expression of normal or mutated ras in 30%￿40% of human cancers, 
including colon cancer, pancreatic carcinoma, and anaplastic and follicular thyroid carcinoma 
(2). As to the ras genes identified so far, mutation of K-ras is most commonly found in human 
tumors, whereas N-ras mutations are encountered less often and H-ras mutations quite rarely (3). 
The high incidence of K-ras mutations in human tumors has motivated much research on the 
development of inhibitors that block the growth of tumors that harbor this mutated oncogene, by 
inhibiting the activity of its product, the p21
ras protein. New therapeutic strategies interfering 
with p21
ras action, and thereby impeding oncogenic ras function in vivo, include the blockade of 
ras gene expression by complementary oligodeoxynucleotides (4) and the inhibition of p21
ras 
farnesylation by farnesyl transferase inhibitors (5). 
 
Endocannabinoids are the endogenous agonists for the cannabinoid receptors, the sites of action 
of marijuana￿s psychotropic principle, (-)∆
9-tetrahydrocannabinol (THC) (6). These substances, 
and particularly anandamide (7), seem to be ubiquitous in mammals (8), and it has been 
suggested that they control cell survival or death (9). This control is not necessarily exerted via 
the two-cannabinoid-receptor subtypes characterized so far. Of these receptors, the CB1 and CB2 
receptors, however, anandamide efficaciously activates only the former (10).Anandamide 
inhibits the proliferation of human breast cancer cells by blocking the G0/G1-S phase transition of 
the cell cycle through CB1 receptor-coupled signal transducing events (11￿13), but no evidence 
exists for an antiproliferative action of this substance in vivo. Conversely, THC inhibits the 
growth of glioma tumors in vivo by inducing cell apoptosis, but the involvement of cannabinoid 
receptors in this effect has not been clarified fully (14). No direct evidence exists for the 
interference of cannabimimetic agents with p21
ras activity. In this study we present evidence that 
anandamide and CB1 receptors in concert are part of an endogenous signaling system that can be 
targeted pharmacologically for the inhibition of K-ras oncogene-dependent cancer growth. We 
induced tumors in nude mice by injection of K-ras-transformed (KiMol) thyroid FRTL-5 cells 
and found that an anandamide analog, by blocking p21
ras activity via CB1 receptors, inhibits the 
growth of these tumors. We also report that the expression of CB1 receptors in healthy and 
transformed FRTL-5 cells is regulated in opposite ways and determines the extent of the 
responsiveness of these cells to endocannabinoids. Our data support the use of anandamide-
based drugs as antitumor drugs. 
 
MATERIALS AND METHODS 
 
Cells and culture  
 
We cultured FRTL-5 cells as described previously (15). KiMol cells, derived from FRTL-5 cells 
on infection and transformation with a wild-type strain of KiMSV-MolMuLV (16, 17), were 
kindly provided by G. Vecchio and A. Fusco (Napoli, Italy). We grew KiMol cells at 37￿C in 
Coon￿s modified Ham￿s F-12 medium, supplemented with 5% calf serum. 
  
 
Cell proliferation assays 
 
Cell proliferation assays were carried out in six-well dishes containing subconfluent cells at a 
density of ~60,000 cells/well. This was according to the method previously described (11). 
 
Tumorigenicity assay 
 
We performed all experiments in 6-week-old male athymic mice. Animals were injected (day 0) 
on the dorsal right side with a suspension of 0.3 ml containing 1 × 10
6 KiMol cells, and the site 
of injection was marked. At day 3 animals were divided in three groups, and 2-methyl-
arachidonyl-2￿-fluoro-ethylamide (Met-F-AEA, Calbiochem, Darnstadt, Germany) or Met-F-
AEA + SR141716A (a kind gift from Sanofi Recherche, Montpellier, France) were dissolved in 
0.2 ml of sterile saline solution (0.9% NaCl) and injected subcutaneously (s.c.) at the previous 
injection site. SR141716A was introduced from a stock solution in dimethylsulphoxyde 
(DMSO), whose final concentration in the injected saline solution was <0.1%. Before injection, 
the solutions were sonicated in order to facilitate the solution of lipophilic components. Saline 
solution was used for the injection of the control group. Treatment was repeated at 72-h 
intervals. Tumor diameters were measured with calipers every other day until the animals were 
killed. Tumor volumes (V) were calculated by the formula of rotational ellipsoid: V= A × B
2/2 
(A = axial diameter, B = rotational diameter). After 20 days in the control group, tumor burden 
was exceeding 10% of the host weight and, therefore, according to the regulation for animal 
welfare, the experiment was stopped, the animals were killed, and the tumor weight was 
evaluated. During the treatment, none of mice showed signs of wasting or other visible 
indications of toxicity. Furthermore, the dose of Met-F-AEA showed no detectable reduction of 
the spontaneous activity, as we observed unimpaired locomotion of the treated mice. All mice 
were maintained at the Dipartimento di Biologia e Patologia animal facility, and all animal 
studies were conducted in accordance with the Italian regulation for the welfare of animals in 
experimental neoplasia. 
 
Western immunoblot 
 
We prepared cell extracts from subconfluent cells grown in 100-mm petri dishes. Cells were 
washed twice in phosphate buffered saline (PBS), scraped in PBS, and pelleted by centrifugation. 
Cell pellets were resuspended in lysis  buffer (10 mM Tris-HCl, pH 7.2; 1 mM 
phenylmethylsulphonylfluoride; 2 µM aprotinin; and 10 µM leupeptin) disrupted by sonication 
and centrifuged at 3,000 rpm for 10 min at 4￿C. Protein (50 ￿g) from liver homogenates and cell 
supernatants were electrophoresed on 12% sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to nitrocellulose membrane, and blocked with 7.5% 
milk in tris-buffered saline-Tween 20 for 1 h at room temperature. The filters were then probed 
with CB1 receptor polyclonal antibodies (Cayman, East Lansing, MI) at a 1:500 dilution. 
Immunoreactive proteins were detected by incubation with horseradish peroxidase-conjugated 
donkey anti rabbit IgG (BioRad, Hercules, CA), by using the enhanced chemiluminescence 
system (ECL, Amersham, Buckinghamshire, U.K.). The coefficient of analytical variations of 
Western blot experiments was 4%. 
 
 
  
Immunofluorescence microscopy 
 
KiMol cells grown on coverslip glasses were incubated for 24 h in culture medium containing 
5% calf serum in the presence or in the absence of 10 µM Met-F-AEA. The cells were then 
fixed with 3.7% paraformaldehyde and were permeabilized or not with 0.05% Triton X-100. 
The primary antibody anti CB1 receptor was the same used for Western blot experiments. The 
secondary antibodies were tetramethyl rhodamine isothiocyanate-conjugated anti rabbit IgG 
(Sigma, St. Louis, MO). We determined nonspecific labeling similarly, except that we 
substituted nonimmune rabbit antiserum for anti-CB1 receptor antibodies. Coverslips were 
mounted on 50% glycerol in PBS and examined by fluorescence microscopy (18). 
 
p21
ras activity assay 
 
Ras activity was assayed by affinity precipitation by using a Ras Activation Assay Kit (Upstate 
Biotechnology, Lake Placid, NY). Briefly, 4 × 10
6 KiMol cells and tumors were treated with 
Met-F-AEA or vehicle as previously described. Cells were then lysed with lysis buffer (125 mM 
Hepes, pH 7.5; 750 mM NaCl; 5% Igepal CA630; 50 mM MgCl2; 5 mM ethylenediamine-
tetraacticacid (EDTA); and 10% glycerol) and incubated with 5 ￿l of a 50% slurry of Raf-1 RBD 
(ras binding domain peptide) for 30 min at 4￿C. The beads were then boiled in reducing sample 
buffer, adsorbed proteins were resolved by electrophoresis transferred to nitrocellulose and 
probed with a monoclonal anti-Ras (MLB, Raf-1 RBD, and anti-Ras were included in a Ras 
Activation Assay Kit, Upstate Biotechnology). We visualized proteins by using a horseradish 
peroxidase-conjugated secondary antibody and ECL. 
 
RT-PCR amplification of CB1 mRNA 
 
Total RNA was prepared from FRTL-5 cells and rat thyroids by Trizolﬁ method (Life 
Technologies, Rockville, MD), according to manufacturer information. To remove contaminant 
DNA, we followed DNA-free (Ambion) protocol to DNase digest 12 ￿g of RNA samples. Retro-
transcription of mRNA into cDNA was performed in a 20 ￿l reaction mixture containing 75 mM 
KCl; 3 mM MgCl2; 10 mM dithiothreitol; 1 mM dNTPs; 50 mM Tris-HCl, pH 8.3; 5 ￿g total 
RNA; 20 units of RNAse inhibitor (Boehringer-Roche, Mannheim, Germany); 0.125 A260 units 
of hexanucleotide mixture (Boehringer-Roche) for random-priming; and 200 units of MoMuLV 
reverse transcriptase (Superscript, GIBCO, Rockville, MD). The reaction mixture was incubated 
at room temperature for 10 min and at 37￿C for 90 min. The incubation was stopped by heating 
at 98￿C for 5 min, and the mixture was cooled in ice and stored to ￿20￿C. Control samples (no-
RT) were prepared by omitting MoMuLV reverse transcriptase in the retrotrascription mixture. 
DNA amplification was performed in a 50 ￿l polymerase chain reaction (PCR) mixture 
containing: 0.5￿2 ￿l of the retrotrascription mixture, 1× PCR buffer (supplied as component of 
the DNA polymerase kit), 3 mM MgCl2, 250 ￿M dNTPs, 0.5 ￿M each of 5’ and 3’ primers, and 
2.5 units of Platinum® Taq DNA polymerase (Life Technologies). We amplified the mixture in 
a PE Gene Amp PCR System 2400 thermocycler (Perkin Elmer, Foster City, CA). The primers 
used were CB1 sense primer, 5’- GGAGAACATCCAGTGTGGGG-3’; CB1 antisense primer 5’-
CATTGGGGCTGTCTTTACGG-3’ (*) β-beta-actin sense primer 5’-GGCATCCTGACCCTGAAGTACCCC -3’; 
β-beta-actin antisense primer 5’-AGACGCAGGATGGCATGAGGGAGC-3’. The amplification profile for CB1 
consisted of an initial denaturation of 2 min at 95￿C; 15 cycles of pre-PCR: 30 s at 95￿C, annealing 
  
for 30 s at 60￿C (0.2￿C decrease for each successive cycle), elongation for 2 min at 72￿C; 10￿20 
cycles of PCR, 30 s at 95￿C, annealing for 30 s at 57￿C, elongation for 60￿155 s at 72￿C (5 s of 
time elongation for each successive cycle). The amplification profile for β-actin consisted of an 
initial denaturation of 2 min at 95￿C and 20￿35 cycles of 30 s at 95￿C, annealing for 1 min at 
60￿C and elongation for 2 min at 72￿C. A final extension of 10 min was carried out at 72￿C. The 
expected sizes of the amplicons were 284 bp for CB1 and 348 bp for β-actin. The β-actin 
housekeeping gene expression was used in order to evaluate variations in the mRNA quality and 
content and to monitor cDNA synthesis in the different preparations. Furthermore the PCR 
primers β-actin were selected by including an intron sequence; consequently, in the presence of 
contaminant genomic DNA, the expected size of the β-actin amplicon would be 811 bp. 
Quantification of expression levels was performed in the exponential phase of amplification 
determined, for a fixed quantity of retrotrascription mixture, by analyzing the amount of 
amplicon synthesized at different numbers of amplification cycles. PCR products (10￿20 ￿l) 
were electrophoresed on 2% agarose gel (MS agarose, Boehringer-Roche) in 1× TAE buffer at 4 
V/cm for 4 h. We included ethidium bromide (0.1 ￿g/ml) in both the gel and the electrophoresis 
buffer, and PCR products were detected by UV visualization. 
 
Flow cytometry analysis 
 
We performed flow cytometry by collecting floating cells and adherent cells obtained by 
trypsin/EDTA, washing them in cold PBS, and fixing them in 70% cold ethanol for 30 min. 
Ethanol was removed by PBS wash, and cells were incubated in PBS, 50 µg/ml propidium 
iodide, 10 µg/ml RNase A DNase-free overnight at 4￿C. Cells were then analyzed by flow 
cytometry by using a FACScan (Becton Dickinson and Co., Mountain View, CA). 
 
RESULTS AND DISCUSSION 
 
Because anandamide is metabolized rapidly in vivo (6), we used a metabolically stable analog, 
Met-F-AEA (19). The effect of Met-F-AEA in vivo was evaluated in a nude mouse xenograft 
model, where KiMol cells were implanted s.c. KiMol cells can induce the growth of 
undifferentiated carcinomas when injected s.c. into syngenic animals or athymic mice (20). In 
order to evaluate the efficacy of Met-F-AEA treatment in vivo on the growth of thyroid KiMol 
cells, we inoculated s.c. 30 athymic mice with 1 × 10
6 KiMol cells. After two days, animals were 
injected with saline solution containing Met-F-AEA. Saline solution was injected in the control 
group. Met-F-AEA was injected s.c. in the peri-tumoral area on days 2 and 5 of a 7-day cycle, 
for 3 cycles. Met-F-AEA treatment (0.5 mg/kg/dose) induced a drastic reduction in tumor weight 
(~80%) with respect to the vehicle-control treated mice, with no detectable toxic or 
hypolocomotor effects on the treated animals (Fig. 1). This effect was inhibited significantly by 
the CB1 receptor antagonist SR141716A (21) (0.7 mg/kg/dose, s.c. intra-tumor) (Fig. 1), thus 
suggesting the involvement of CB1 receptors in the tumor growth inhibitory effect of Met-F-
AEA. Although no statistically significant difference was observed at any time point between 
tumor size in control animals or in animals treated with Met-F-AEA plus SR141716A, blockade 
of the antitumor effect of the anandamide analog by the CB1 receptor antagonist appeared to be 
incomplete at the dose used. Because cannabinoid CB2 receptors have been suggested recently to 
mediate the inhibitory effect of cannabinoids on glioma growth in vivo (22), we cannot rule out 
the participation of this receptor subtype to the antitumor effect of Met-F-AEA. However, this 
  
anandamide analog was shown previously to have much lower affinity for CB2 than CB1 
cannabinoid receptors (19). The participation of CB1 receptors to the tumor-growth inhibitory 
effect of Met-F-AEA was also supported by the finding, in tumor tissue, of a CB1 mRNA 
transcript, as detected by RT-PCR technique, and of a CB1-immunoreactive receptor protein as 
detected by Western immunoblotting (Fig. 2a, b). The sizes of both the mRNA transcript and the 
immuno-reactive protein were compatible to what expected for CB1 receptors. Furthermore the 
immuno-reactive band disappeared if the gel was co-incubated with the immunizing peptide (not 
shown). The antitumor effect of Met-F-AEA was accompanied by a strong decrease in of p21
ras 
activity in tumors, which was attenuated significantly by SR 141716A (Fig. 3, upper panel). 
 
We also looked at the effect of Met-F-AEA on KiMol cells in vitro and found that the 
anandamide analog (10 µM) inhibits their proliferation. After a 24-h treatment, cells had 
proliferated ~36% less than vehicle-treated cells (P<0.05 by ANOVA). By contrast, the 
proliferation of nontransformed FRTL-5 cells after a 24-h treatment was not affected by 10 µM 
Met-F-AEA (9% inhibition, not statistically significant by ANOVA, see below). The effect of 
Met-F-AEA was not due to toxicity or to apoptosis of cells, but instead to the dose-dependent 
(IC50 = 5 µM) arrest of the cell cycle at the G0/G1 phase, associated with a significant reduction 
of cells in the S and G2/M phase, as shown by cytofluorimetric analysis (Fig. 4). The 
antiproliferative effect was accompanied by a striking reduction of p21
ras activity (Fig. 3, lower 
panel). All these effects were attenuated significantly by SR141716A (0.1 µM) (Fig. 3, lower 
panel, and Fig. 4). In fact, also KiMol cells expressed a CB1 mRNA transcript and a CB1-
immunoreactive protein (Fig. 2b). 
 
These findings indicate that two fundamental components of the endogenous cannabinoid 
system; that is, the endocannabinoids and the cannabinoid CB1 receptor represent a potentially 
useful target for the development of therapeutic agents controlling ras oncogene-dependent 
tumor growth. 
 
Finally, we assessed whether cannabinoid CB1 receptors are regulated during endocannabinoid 
inhibition of tumor development. We were surprised to find that the decrease in tumor volume 
induced by Met-F-AEA was accompanied by a strong up-regulation of CB1 receptor mRNA and 
protein compared with vehicle-treated tumors (Fig. 5a, b). Similarly, KiMol cells treated with 
Met-F-AEA expressed significantly more CB1 receptors, and this effect was abolished by 
SR141716A (0.1 µM) (Fig. 5c). Cell immunofluorescence studies with both permeabilized and 
nonpermeabilized cells showed that Met-F-AEA increased the levels of CB1 receptors both on 
the cell membrane and in the cytosol (Fig. 6). By contrast, nontransformed FRTL-5 cells treated 
with Met-F-AEA exhibited less CB1 receptors than vehicle-treated cells in both the cell 
membrane and cytosol, as assessed by Western immunoblot (Fig. 5d) and immunofluorescence 
analysis (Fig. 6). This finding agrees with the down-regulation of the expression of CB1 
receptors generally observed in several healthy cell types and tissues after chronic exposure to 
CB1 receptor agonists (10). In accordance with this opposite regulation of CB1 receptor 
expression in transformed vs. healthy cells, we found that after we treated cells with 10 µM Met-
F-AEA, the proliferation of Ki Mol cells was significantly more strongly inhibited by the 
cannabimimetic substance (up to 70% inhibition) than the response of FRTL-5 cells, which 
barely reached statistical significance after 3 days (up to 28% inhibition, Fig. 7). 
 
  
Previous observations have shown that THC can effectively reduce the growth of glioma tumors 
in mice by inducing apoptosis of glioma cancer cells (14). This effect was blocked by a 
combination of CB1 and CB2 cannabinoid receptor antagonists but not by each antagonist alone, 
thus leaving the role of each cannabinoid receptor subtype in this effect still to be fully clarified. 
Furthermore, the apoptotic effect of THC in glioma cells appeared to be mediated by 
sphingomyelin hydrolysis and ceramide formation (14, 23). More recent studies have confirmed 
the role of this signaling pathway in cannabinoid-induced inhibition of glioma cell growth (24). 
By contrast, we have reported previously that the cytostatic effect of anandamide on human 
breast and prostate cancer cells was due to activation of CB1 receptors (11, 13), inhibition of 
cAMP-mediated signaling and/or activation of p42/p44 extracellular regulated kinases (ERK) 
(12), and inhibition of the expression of the receptors for prolactin and nerve growth factor, 
which act as mitogenic factors for these cells (13). Therefore, we believe that the data presented 
here are important inasmuch as they indicate for the first time that: 1) anandamide analogs, 
which have a lower potential for physical dependence than THC and synthetic cannabinoids (25), 
inhibit tumor growth also in vivo, and at nonpsychotropic doses; 2) the antitumor effects of these 
substances in vivo can be exerted through CB1 cannabinoid receptors and via inhibition of p21
ras 
activity; and 3) anandamide analogs inhibit the growth of epithelial tumors and, in particular, 
those derived from KiMol thyroid cells. Indeed, it should be emphasized that epithelial cell-
derived tumor models may have particular importance because the large majority of human 
neoplasias are epithelial in origin (26). Further work will be necessary to establish the exact 
molecular mechanism of Met-F-AEA-induced suppression of p21
ras activity. It has been shown 
recently that endocannabinoids stimulate ERK, c-Jun amino-terminal kinases (JNK), and p38 
mitogen activated protein kinases (MAPKs) in several cell lines via CB1/CB2 receptor-dependent 
and independent mechanisms (12, 27￿29), whereas an inhibitor of p21
ras farnesyltransferase was 
shown to attenuate the CB1-mediated activation of JNK (28). Hence, on the basis of data 
reported here and previously, we speculate that, by modulating the activity of both p21
ras and 
MAPKs, the CB1 receptor may regulate the fate of cancer cells (e.g., cessation of proliferation 
and/or apoptosis). 
 
Another important finding described here is that CB1 receptors may be regulated by 
endocannabinoids in KiMol cells in a manner entirely different from that observed with 
nontransformed cells, thus allowing cancer cells, but not healthy cells, to respond ever more 
efficaciously to the antiproliferative effect of CB1 agonists. Indeed, we found that transformed 
cells in culture become ever more responsive to Met-F-AEA, whereas nontransformed cells do 
not. We speculate that this phenomenon may contribute to the putative tumor-suppressing role 
proposed for endocannabinoids in previous studies (9, 11, 30). Furthermore, this finding 
indicates that Met-F-AEA can inhibit the growth of cancer thyroid cells much more effectively 
than healthy, nontransformed cells can, and strengthens our proposal that endocannabinoid-based 
drugs should be kept into account as novel antitumor agents. 
 
CONCLUSIONS 
 
In conclusion, we have shown here that anandamide-based drugs may be efficacious drugs for 
the inhibition of K-ras-induced epithelial cancer cell growth in vivo through the activation of 
CB1 receptors, inhibition of p21
ras activity, and blockade of the cell cycle. Because multiple 
pathways are important for the proliferation of tumor cells and because combination therapies 
  
are often more effective than single-drug administration, cannabimimetic substances may 
complement other anticancer agents that may or may not affect K-ras-mediated pathways. 
Because THC-like compounds are used to inhibit nausea and induce appetite in cancer patients, 
and anandamide appears to be an endogenous orexigenic mediator (31), the finding of possible 
antitumor effect for these substances might have a tremendous potential for therapeutic 
intervention in preventing the progression of cancer and, at the same time, in alleviating its 
symptoms. 
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 Fig. 1 
 
                          
 
Figure 1. Met-F-AEA inhibits growth of KiMol-induced tumors in athymic mice. A) Tumor volume at different days 
from inoculation. To evaluate the efficacy of treatment in vivo on the growth of thyroid KiMol cells, we inoculated 30 
athymic mice subcutaneously with 1 ×  10
6 KiMol cells. After 3 days, animals were divided into three groups; Met-F-AEA 
or Met-F-AEA plus the CB1 receptor antagonist SR141716A were injected subcutaneously at the previous injection site. 
Saline solution was used for the injection of the control group. Treatment was repeated at 72-h intervals, and tumor 
diameters were measured. After 4 weeks in the control group, tumor burden exceeded 10% of the host weight. Therefore, 
animals were killed and tumor volume was evaluated. Data are mean ± SE of n = 10. Differences in tumor volumes after 4 
weeks were significant (P<0.01 by ANOVA followed by Bonferroni’s Test) between the control and Met-F-AEA groups 
and between the Met-F-AEA and the Met-F-AEA + SR141716A groups. B) Representative tumors excised from mice 
after 4 weeks of treatment with vehicle, Met-F-AEA, or Met-F-AEA + SR141716A. Fig. 2 
 
 
                     
Figure 2. Molecular characterization of CB1 receptors in K-ras transformed FRTL-5 cells and in tumors derived 
from these cells. A) Identification by RT-PCR of a CB1 transcript in the RNA from KiMol cell-derived tumors. The 
transcript was of the size expected from the use of the oligoprobes described in the Materials and Methods. STD indicates 
the lane where the base pair ladder was loaded. B) Western immunoblot of proteins from KiMol cells and the derived 
tumor. Molecular weight markers are shown. The size of the immunoreactive protein was compatible with that reported 
for cannabinoid CB1 receptors (10). The gel and the blot are representative of three different experiments. Fig. 3 
 
                                
                     
Figure 3. Met-F-AEA inhibition of p21
ras activity in KiMol cells, and in tumors derived from these cells. 
Upper gel: tumors obtained by subcutaneous injection of KiMol cells from vehicle-treated mice, Met-F-AEA-treated 
mice, and Met-F-AEA plus SR141716A-treated mice were processed for the assay of p21
ras activity as described in 
Materials and Methods. Lower gel: KiMol cells were incubated with 10 µM Met-F-AEA, in the presence of 0.1 µM 
SR141617 or vehicle, for 24 h, and processed for the assay of p21
ras activity as described in Materials and Methods. The 
same amounts of proteins (50 µg) were loaded in each lane. The data presented are representative of three experiments 
yielding very similar results. Densitometric analysis of the gel bands gave the following results (in arbitrary units): (upper 
gel) control 5192 ± 233; Met-F-AEA, 3105 ± 155; Met-F-AEA ± SR141716A, 4456 ± 254; (lower gel) control 4216 
± 199; Met-F-AEA, 1802 ± 126; Met-F-AEA ± SR141716A, 3456 ± 211 (mean ± SE, n=3). Fig. 4 
 
             
                    
Figure 4. Dose-dependent accumulation of KiMol cells in the Gi/Go phase and reduction in the S phase of the cell 
cycle by Met-F-AEA. Samples were collected at 24 h, in the presence of different concentrations of Met-F-AEA, and 
then were analyzed for DNA content by flow cytometry. The effect of the CB1 selective antagonist, SR141617A (0.1 µM) 
on Met-F-AEA (20 µM) inhibition of KiMol cell proliferation, is shown (full circles) and was statistically significant 
(P<0.05, for the G0/G1 phase, and P<0.01 for the S and G2/M phases, by ANOVA). Fig. 5 
 
                            
                    
Figure 5. Met-F-AEA treatment exerted opposite effects on the expression of CB1 receptors in either Ki Mol cell-
derived tumors and KiMol cells or in healthy FRTL-5 cells. Tumors and cells were obtained as described previously 
and were processed for the determination of CB1 receptor RNA levels, by RT-PCR (A), and of CB1 receptor levels, by 
Western immunoblot (B–D), as described in Materials and Methods. Lane 1, vehicle-treated cells and tumors; lane 2, cells 
and tumors treated with Met-F-AEA (10 µM and 0.5 mg/kg/treatment subcutaneously, respectively); lane 3, cells and 
tumors treated with Met-F-AEA (10 µM and 0.5 mg/kg/treatment subcutaneously, respectively) + SR141716A (0.1 µM 
and 0.7 mg/kg/treatment subcutaneously, respectively). In (B–D) the same amounts of proteins (50 µg) were loaded in 
each lane. Gels are representative of three experiments yielding very similar results. Fig. 6 
 
                                
                    
Figure 6. Immunofluorescence of CB1-receptors in KiMol and FRTL-5 cells. Cells were pre-incubated for 
24 h in the absence (control) and in the presence of 10 µM Met-F-AEA and/or 0.1 µM SR141716A before processing for 
the immunostaining of CB1-receptors. The figure is representative of three independent experiments. Cells were 
either permeabilized (A, B, F, G) or not (C, D, E) with 0.05% Triton X-100. Fig. 7 
 
                                  
                    
Figure 7. Effects of Met-F-AEA on normal and K-ras-transformed FRTL-5 cell proliferation. Time-dependent 
inhibition of FRTL-5 (full circles) and KiMol (empty circles) cell proliferation by 10 µM Met-F-AEA. Data are mean ± SE 
(n=3) and are expressed as percentages of cell proliferation. 